Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
AssigneeAutotelic LLC
InventorVuong Trieu
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions, including antibodies or fragments or derivatives thereof, and related devices and methods effective for detecting and quantifying olmesartan in a sample. The compositions, devices, and methods can be applied to improve the effectiveness of hypertension therapy by monitoring a subject's compliance by determining one or more pharmacokinetic parameters of the subject with a point-of-care device after antihypertensive drug administration. In one embodiment, the antihypertensive drug is olmesartan and the pharmacokinetic parameter is AUC.
Claims12
A method of detecting the presence of olmesartan in a sample, comprising:
- contacting the sample to an anti-olmesartan antibody or antigen-binding fragment or derivative thereof labeled with a detectable reporting group under conditions sufficient to permit binding of olmesartan in the sample with the antibody or antigen-binding fragment or derivative thereof, wherein the anti-olmesartan antibody is a monoclonal antibody and the antibody or antigen-binding fragment or derivative thereof has a 50% binding of immobilized olmesartan at between 2.0 and 5.0 ppb free olmesartan in a competitive ELISA;
- and
- detecting the binding of the olmesartan to the antibody or antigen-binding fragment or derivative thereof, wherein the detecting the presence of olmesartan in the sample is performed in a lateral flow assay format.
Dependencies are inferred from the claim text.